Issue Date: January 23, 2017
Pharma partnership applies deep learning to very big data
GlaxoSmithKline has for several years engaged in a campaign of creative destruction, acting to replace traditional methods of manufacturing and research with more efficient ways of doing things. The implementation of programs such as its Manufacturing Technology Roadmap, a manifesto against the standard pharma method of manufacturing drugs in batches, for example, has helped earn the company the reputation of risk-taker among major drug firms.
Now, GSK is turning its attention to drug discovery, where . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society